Intellia Therapeutics CEO John Leonard has, for the last couple years, found himself stuck in a financial Groundhog Day.
With a bunch of gene therapy and gene editing programs in clinical trials, CRISPR Therapeutics (NASDAQ: CRSP) has an ...
Clinical Trial Success at Cincinnati Children's Supports Recent US FDA Approval for First Therapy to Directly Replace a Gene in the Brain ...
On Thursday, Bluebird Bio Inc. (NASDAQ:BLUE) reported a third-quarter EPS loss of 31 cents, compared to a loss of 80 cents a ...
As novel gene therapies emerge, there is a complex interplay among their potential benefits, the burdens they may impose and ...
The FDA has accepted for review the resubmitted BLA for prademagene zamikeracel for recessive dystrophic epidermolysis bullosa.
Bluebird has just two quarters until it’s out of cash. Executives are looking for financing to extend that runway to a ...
(NASDAQ:BLUE) traded lower for the fourth straight session as Bank of America and J.P. Morgan downgraded the gene therapy developer after its Q3 2024 results fell short of expectations for ...
Harvard Medical School researchers have taken another decisive step in their efforts to develop a gene therapy for people ...
Understanding what to patent versus what to keep as a trade secret is an increasingly important and challenging decision ...
Put up against placebo in the phase 3 EMBARK trial, delandistrogene moxeparvovec (Elevidys) did not significantly improve ...
Harvard Medical School researchers have taken another decisive step in their efforts to develop a gene therapy for people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback